S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:OMCL - Omnicell Stock Price, Forecast & News

$81.52
-3.42 (-4.03 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$81.35
Now: $81.52
$85.90
50-Day Range
$81.28
MA: $85.64
$90.19
52-Week Range
$67.30
Now: $81.52
$94.85
Volume249,800 shs
Average Volume202,513 shs
Market Capitalization$3.42 billion
P/E Ratio57.41
Dividend YieldN/A
Beta1.12
Omnicell, Inc provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication adherence solutions for the healthcare industry worldwide. It operates in two segments, Automation and Analytics, and Medication Adherence. The Automation and Analytics segment offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. Read More…

Industry, Sector and Symbol

Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$897.03 million
Cash Flow$3.65 per share
Book Value$20.16 per share

Profitability

Net Income$61.34 million

Miscellaneous

Employees2,480
Market Cap$3.42 billion
Next Earnings Date4/23/2020 (Estimated)
OptionableOptionable

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.


Omnicell (NASDAQ:OMCL) Frequently Asked Questions

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Thursday, February, 6th. The company reported $0.77 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.78 by $0.01. The company had revenue of $248.29 million for the quarter, compared to analyst estimates of $243.69 million. Omnicell had a return on equity of 11.76% and a net margin of 6.84%. The business's quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.70 EPS. View Omnicell's Earnings History.

When is Omnicell's next earnings date?

Omnicell is scheduled to release their next quarterly earnings announcement on Thursday, April 23rd 2020. View Earnings Estimates for Omnicell.

What guidance has Omnicell issued on next quarter's earnings?

Omnicell updated its FY20 earnings guidance on Thursday, February, 6th. The company provided earnings per share guidance of $2.96-3.16 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.00. The company issued revenue guidance of $1.00-1.02 billion, compared to the consensus revenue estimate of $991.00 million.

What price target have analysts set for OMCL?

7 Wall Street analysts have issued 12-month target prices for Omnicell's shares. Their forecasts range from $82.00 to $100.00. On average, they expect Omnicell's stock price to reach $89.29 in the next twelve months. This suggests a possible upside of 9.5% from the stock's current price. View Analyst Price Targets for Omnicell.

What is the consensus analysts' recommendation for Omnicell?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.

Has Omnicell been receiving favorable news coverage?

News stories about OMCL stock have trended somewhat positive on Thursday, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Omnicell earned a media sentiment score of 1.5 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Omnicell.

Are investors shorting Omnicell?

Omnicell saw a decrease in short interest in January. As of January 31st, there was short interest totalling 2,070,000 shares, a decrease of 5.9% from the January 15th total of 2,200,000 shares. Based on an average daily trading volume, of 229,000 shares, the days-to-cover ratio is presently 9.0 days. Approximately 5.0% of the shares of the stock are short sold. View Omnicell's Current Options Chain.

Who are some of Omnicell's key competitors?

What other stocks do shareholders of Omnicell own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), Netflix (NFLX), AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Adobe (ADBE), Micron Technology (MU), Alibaba Group (BABA), Bank of America (BAC) and Gilead Sciences (GILD).

Who are Omnicell's key executives?

Omnicell's management team includes the folowing people:
  • Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)
  • Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)
  • Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)
  • Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)
  • Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 46)

Who are Omnicell's major shareholders?

Omnicell's stock is owned by many different of institutional and retail investors. Top institutional investors include Conestoga Capital Advisors LLC (3.76%), Credit Suisse AG (3.51%), State Street Corp (2.88%), Eagle Asset Management Inc. (2.00%), Janus Henderson Group PLC (1.65%) and Geode Capital Management LLC (1.37%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View Institutional Ownership Trends for Omnicell.

Which major investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Braun Stacey Associates Inc., Redwood Investments LLC, AQR Capital Management LLC, PNC Financial Services Group Inc., Charles Schwab Investment Management Inc., Falcon Point Capital LLC, Westwood Holdings Group Inc. and First Trust Advisors LP. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Scott Peter Seidelmann. View Insider Buying and Selling for Omnicell.

Which major investors are buying Omnicell stock?

OMCL stock was purchased by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Credit Suisse AG, Trillium Asset Management LLC, Bank of America Corp DE, WCM Investment Management LLC, Great West Life Assurance Co. Can, Summit Creek Advisors LLC and Fiera Capital Corp. View Insider Buying and Selling for Omnicell.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $81.52.

How big of a company is Omnicell?

Omnicell has a market capitalization of $3.42 billion and generates $897.03 million in revenue each year. The company earns $61.34 million in net income (profit) each year or $2.19 on an earnings per share basis. Omnicell employs 2,480 workers across the globe.View Additional Information About Omnicell.

What is Omnicell's official website?

The official website for Omnicell is http://www.omnicell.com/.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]


MarketBeat Community Rating for Omnicell (NASDAQ OMCL)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  446 (Vote Outperform)
Underperform Votes:  344 (Vote Underperform)
Total Votes:  790
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Featured Article: What is Green Investing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel